NasdaqGS:ADXS

Stock Analysis Report

Executive Summary

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Advaxis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ADXS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.4%

ADXS

0.5%

US Biotechs

0.06%

US Market


1 Year Return

-82.1%

ADXS

14.1%

US Biotechs

19.3%

US Market

Return vs Industry: ADXS underperformed the US Biotechs industry which returned 14.1% over the past year.

Return vs Market: ADXS underperformed the US Market which returned 19.3% over the past year.


Shareholder returns

ADXSIndustryMarket
7 Day-3.4%0.5%0.06%
30 Day0.6%2.8%1.7%
90 Day120.6%8.2%9.0%
1 Year-82.1%-82.1%15.0%14.1%21.8%19.3%
3 Year-99.2%-99.2%24.2%20.9%49.5%39.9%
5 Year-99.3%-99.3%3.1%-1.7%73.1%54.1%

Price Volatility Vs. Market

How volatile is Advaxis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Advaxis undervalued compared to its fair value and its price relative to the market?

1.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ADXS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ADXS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ADXS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ADXS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADXS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADXS is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Advaxis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-120.0%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ADXS's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if ADXS's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ADXS's revenue is expected to decline over the next 3 years (-120% per year).

High Growth Revenue: ADXS's revenue is forecast to decline over the next 3 years (-120% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADXS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Advaxis performed over the past 5 years?

-4.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADXS is currently unprofitable.

Growing Profit Margin: ADXS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADXS is unprofitable, and losses have increased over the past 5 years at a rate of -4.4% per year.

Accelerating Growth: Unable to compare ADXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADXS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64%).


Return on Equity

High ROE: ADXS has a negative Return on Equity (-42.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Advaxis's financial position?


Financial Position Analysis

Short Term Liabilities: ADXS's short term assets ($36.1M) exceed its short term liabilities ($4.5M).

Long Term Liabilities: ADXS's short term assets ($36.1M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: ADXS is debt free.

Reducing Debt: ADXS has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.


Balance Sheet

Inventory Level: ADXS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ADXS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADXS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ADXS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25.9% each year


Next Steps

Dividend

What is Advaxis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ADXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ADXS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADXS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADXS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Ken Berlin (55yo)

1.8yrs

Tenure

US$1,797,456

Compensation

Mr. Kenneth A. Berlin, also known as Ken, J.D., serves as President, Chief Executive Officer and Director of Advaxis, Inc. since April 23, 2018. He served as the Chief Executive Officer and President of Ro ...


CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD1.80M) is above average for companies of similar size in the US market ($USD521.37K).

Compensation vs Earnings: Insufficient data to compare Ken's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Berlin
President1.8yrsUS$1.80m0.018% $10.3k
Molly Henderson
Executive VP1.7yrsUS$521.87k0.0097% $5.7k
Andres Gutierrez
Executive VP & Chief Medical Officer1.8yrsno data0.0062% $3.7k

1.8yrs

Average Tenure

55yo

Average Age

Experienced Management: ADXS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kenneth Berlin
President1.8yrsUS$1.80m0.018% $10.3k
Richard Berman
Independent Director14.4yrsUS$141.60k0.0062% $3.6k
Roni Appel
Independent Director15.3yrsUS$122.50k0.022% $13.1k
James Patton
Independent Vice Chairman of the Board0yrsUS$189.25k0.032% $18.6k
David Sidransky
Chairman4.8yrsUS$203.55k0.012% $7.2k
Jedd Wolchok
Member of Scientific Advisory Board0yrsno datano data
Antoni Ribas
Member of Scientific Advisory Board0yrsno datano data
Robert Petit
Chairman of Scientific Advisory Board0.7yrsUS$730.69k0.021% $12.5k
Samir Khleif
Independent Director5.3yrsUS$130.00k0.0077% $4.5k
Nancy Freitag
Member of Scientific Advisory Board0yrsno datano data

5.0yrs

Average Tenure

59yo

Average Age

Experienced Board: ADXS's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 342.7%.


Top Shareholders

Company Information

Advaxis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advaxis, Inc.
  • Ticker: ADXS
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$58.736m
  • Shares outstanding: 60.21m
  • Website: https://www.advaxis.com

Number of Employees


Location

  • Advaxis, Inc.
  • 305 College Road East
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADXSNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJul 2005
FAD2DB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2005

Biography

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient’s tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/22 01:50
End of Day Share Price2020/02/21 00:00
Earnings2019/10/31
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.